A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction (Q38169257)

From Wikidata

Jump to navigation Jump to search

scientific article published on 09 December 2013

Language	Label	Description	Also known as
English	A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction	scientific article published on 09 December 2013

Statements

scholarly article

1 reference

Europe PubMed Central

30 August 2017

0 references

A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction (English)

1 reference

Europe PubMed Central

30 August 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Jonathan B Angel

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24314017%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

J Baril

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24314017%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

B Conway

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24314017%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

P Giguère

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24314017%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

N Ferko

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24314017%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

S Hollmann

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24314017%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

publication date

9 December 2013

1 reference

Europe PubMed Central

30 August 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24314017%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24314017%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24314017%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

301-310

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24314017%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

1 reference

https://api.crossref.org/works/10.1111%2FHIV.12118

21 January 2018

Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen

1 reference

https://api.crossref.org/works/10.1111%2FHIV.12118

21 January 2018

A review of low-dose ritonavir in protease inhibitor combination therapy

1 reference

https://api.crossref.org/works/10.1111%2FHIV.12118

21 January 2018

Combination antiretroviral therapy and the risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1111%2FHIV.12118

21 January 2018

Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1111%2FHIV.12118

21 January 2018

The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations

1 reference

https://api.crossref.org/works/10.1111%2FHIV.12118

21 January 2018

Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FHIV.12118

21 January 2018

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1111%2FHIV.12118

21 January 2018

Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use.

1 reference

https://api.crossref.org/works/10.1111%2FHIV.12118

21 January 2018

96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients

1 reference

https://api.crossref.org/works/10.1111%2FHIV.12118

21 January 2018

Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial

1 reference

https://api.crossref.org/works/10.1111%2FHIV.12118

21 January 2018

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results

1 reference

https://api.crossref.org/works/10.1111%2FHIV.12118

21 January 2018

Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study

1 reference

https://api.crossref.org/works/10.1111%2FHIV.12118

21 January 2018

Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.

1 reference

https://api.crossref.org/works/10.1111%2FHIV.12118

21 January 2018

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

1 reference

https://api.crossref.org/works/10.1111%2FHIV.12118

21 January 2018

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1111%2FHIV.12118

21 January 2018

Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events

1 reference

https://api.crossref.org/works/10.1111%2FHIV.12118

21 January 2018

Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1111%2FHIV.12118

21 January 2018

Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1111%2FHIV.12118

21 January 2018

Identifiers

10.1111/HIV.12118

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24314017%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24314017%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38169257&oldid=1745399991"